Characterization of Stimulant Utilization in a State Medicaid Population

March 28, 2022
poster for Characterization of Stimulant Utilization in a State Medicaid Population
Eliza Anderson, PharmD
Wilson Haong, PharmD, MBA
Michael Jones, PharmD
Diala Nicolas, PharmD, BCPS
Mark Tesell, PharmD, BCPS
Commonwealth Medicine
Kimberly Lenz, PharmD, MBA, FAMCP
Commonwealth Medicine
Thomas Pomfret, PharmD, MPH, BCPS
Commonwealth Medicine

This research assesses the use of prescription stimulants (commonly used for the treatment of attention-deficit/hyperactivity disorder, narcolepsy, and excessive daytime sleepiness) in the Massachusetts Medicaid (MassHealth) population. The research investigated the average doses, member age, diagnoses, and medication formulations. It was concluded that the average daily dose of stimulants in the MassHealth population was below the FDA-approved maximum daily doses. The research was presented at the 2022 American Drug Utilization Review Society (ADURS) Symposium, an annual conference specializing in medication utilization within state Medicaid programs. The ADURS Symposium was held from February 24 through 26, 2022, in Scottsdale, Arizona. 

Characterization of Stimulant Utilization in a State Medicaid Population